FH-MagIC TCR-T / Fred Hutchinson Cancer Center, SignalOne Bio - LARVOL DELTA

ATTAMAGE-A1: Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=1 | Terminated | Sponsor: Fred Hutchinson Cancer Center | N=18 ➔ 1 | Trial completion date: Apr 2023 ➔ Aug 2022 | Suspended ➔ Terminated | Trial primary completion date: Apr 2023 ➔ Aug 2022; Terminated due to slow accrual.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Breast Cancer • Genito-urinary Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • Urothelial Cancer • ALK • HER-2 • HLA-A • MAGEA1 • ROS1